Screener
Gyre Therapeutics, Inc. GYRE Pre-Tax Income
Pre-Tax Income at other companies
Other financials
Where this comes from
Reported directly by Gyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.
The source filing: Gyre Therapeutics, Inc.’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 5:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-340448
| Line item | Three Months Ended June 30, | Six Months Ended June 30, |
|---|---|---|
| Interest income | 941 | 1,797 |
| Other expense, net | (488)) | (301)) |
| Change in fair value of warrant liability | 212 | 2,467 |
| (Loss) Income before income taxes | (1,575)) | 4,265) |
| Benefit (provision) for income taxes | (662) | (1,563)) |
| Net (loss) income | (2,237)) | 2,702) |
| Accretion of Cullgen redeemable convertible preferred stock | (2,642)) | (5,220)) |
| Net loss attributable to noncontrolling interest | (2,835)) | (2,644)) |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Gyre Therapeutics, Inc.'s pre-tax income?
- Gyre Therapeutics, Inc. (GYRE) reported pre-tax income of -$14.43M in Q2 2026.
- How has Gyre Therapeutics, Inc.'s pre-tax income changed year-over-year?
- Gyre Therapeutics, Inc.'s pre-tax income decreased by 816.4% year-over-year, from -$1.58M to -$14.43M.
- What is the long-term trend for Gyre Therapeutics, Inc.'s pre-tax income?
- Over 3 years (2021 to 2025), Gyre Therapeutics, Inc.'s pre-tax income has grown at a -45.2% compound annual growth rate (CAGR), from -$87.93M to $14.44M.
- What does pre-tax income mean?
- Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.
Ask your AI about Gyre Therapeutics, Inc.'s pre-tax income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude